The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels.

导出 LinkOut

翻译打印收藏纠错

作者： Kevin P,Cunningham ^[1] ; Lucie H,Clapp ^[2] ; Alistair,Mathie ^[3] ; Emma L,Veale ^[1]

作者单位： Medway School of Pharmacy, University of Kent and University of Greenwich, Chatham Maritime, United Kingdom. ^[1] Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom. ^[2] Institute of Cardiovascular Science, University College London, London, United Kingdom. ^[3] School of Engineering, Arts, Science and Technology, University of Suffolk, Ipswich, United Kingdom. ^[4]

关键词 BL-1249 K2P channels TASK-1 channel TREK-1 (tandem of pore domain in a weak inwardly rectifying K channel (Twik)-related K channels)TREK-2 channels pulmonary arterial hypertension treprostinil (PubChem CID: 6918140)

DOI 10.3389/fphar.2021.705421

PMID 34267666

发布时间 2021-07-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2021年12卷

705421页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除